MMR-dependent checkpoint activation seems to be important for certain types of chemotherapy but does not elicit anti-cancer effects because MMR-deficient mice with certain types of mutations in which the DNA damage checkpoint response still occurs are predisposed to cancer with MSI49,50. The gene discussed is MRC1; the disease is cancer.